Share

Endocrine Society Discusses ARPA-H with Congress, NIH, and OSTP

When President Joe Biden’s budget for fiscal year 2022 was introduced this summer, many biomedical research advocates took note of a new line item that would direct $6.5 billion over three years to a new Advanced Research Projects Agency for Health (ARPA-H) to be housed at the National Institutes of Health (NIH). While we were...
Share

Tildacerfont Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia

july_trends_jcem cover Patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) may benefit from the drug tildacerfont, according to the results from two Phase 2 clinical studies recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Chris N. Barnes, PhD, of Spruce Biosciences (who funded the trial), point out that...
Share

Devil in the Details: The Impact of the First Interchangeable Biosimilar Insulin

[Editor’s Note: This post has been updated to include comments from Rita Kalyani, MD.] When the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product last month, many were hailing this as a breakthrough in treating diabetes. The impacts could be immediately felt by people rationing their insulin due to cost as...
Share

2021 Visionary: Q&A with Teresa K. Woodruff

woodruff-teresa-kaye-2020 Endocrine News talks with Teresa K. Woodruff, PhD, recipient of the 2021 Endocrine Society Gerald D. Aurbach Award for Outstanding Translational Research about what the award means to her and how she came to focus her life’s work on oncofertility, a phrase that she first coined in 2006.   Teresa K. Woodruff, PhD, is no stranger to...
Share

Recognition and Responsibility

Dominguez Hydelene B. Dominguez, MD, the first winner of the Endocrine Society’s C. Wayne Bardin International Travel Award, talks to Endocrine News about how her Filipino community inspired her to pursue research on radioactive refractory thyroid cancer, as well as her excitement at the prospect of attending ENDO 2022 in Atlanta. Aside from being the first...